Kronos Bio Revenue
Biotechnology Research • 
San Mateo, California, United States • 21-50 Employees
Kronos Bio revenue & valuation
| Annual revenue | $3,079,980 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $9,900,000 |
| Total funding | $155,000,000 |
Key Contacts at Kronos Bio
Deborah Knobelman
President & Interim Chief Executive Officer
Kathleen Guindon
Senior Director, Medical Science Liaison
Hua Gao
Director, Computational Chemistry
Cindy Dodd
Senior Director, Fp&A
Elizabeth Townsend
Director
John Fisher
Associate Director, Operations
Kristin Willard
Sr. Director Of Quality Assurance
Minyun Zhou
Associate Director
Kristin Willard
Director Of Quality
Company overview
| Headquarters | 1300 S El Camino Real, Suite 400, San Mateo, California 94402, US |
| Website | |
| NAICS | 541714 |
| Founded | 2017 |
| Employees | 21-50 |
Kronos Bio Email Formats
Kronos Bio uses 3 email formats. The most common is {first name}{last name} (e.g., johndoe@kronosbio.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@kronosbio.com | 66.7% |
{first initial}.{last name} | j.doe@kronosbio.com | 22.2% |
{first initial}{last name} | jdoe@kronosbio.com | 11.1% |
About Kronos Bio
Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. At Kronos Bio, we have two molecules that have emerged from our product engine. KB-0742, our CDK9 inhibitor, is being evaluated in a phase 1/2 clinical trial as a treatment for patients with MYC-dependent tumors such as triple negative breast cancer, non-small cell lung cancer and ovarian cancer, as well as patients with transcription factor fusion-driven cancers and other transcriptionally addicted cancers including chordomas, sarcomas and small cell lung cancer. Our new development candidate, KB-9558, targets the KAT domain of p300, a critical node of the IRF4 TRN, which is a core oncogenic transcription program that drives multiple myeloma. Additionally, Kronos Bio began a discovery collaboration with Genentech in January 2023. Our companies are working together to advance novel therapies against transcriptional targets in oncology. For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Kronos Bio has 11 employees across 5 departments.
Departments
Number of employees
Kronos Bio Tech Stack
Discover the technologies and tools that power Kronos Bio's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
WordPress themes
Page builders
JavaScript libraries
Font scripts
JavaScript libraries
Webmail
Programming languages
Blogs
Analytics
SEO
Hosting
United Kingdom
Canada
Korea, Republic of
Frequently asked questions
4.8
40,000 users
